文献速递胸部肿瘤放疗放疗物理与技术

粒子治疗用于不可手术II-III期非小细胞肺癌的疗效与安全性:系统评价与Meta分析

Efficacy and safety of particle therapy for inoperable stage II-III non-small cell lung cancer: a systematic review and meta-analysis.
PubMed 文献 · Radiat Oncol · 2023-05-22

该系统评价与Meta分析纳入19项研究共851例不可手术局部晚期非小细胞肺癌患者,评估粒子治疗(碳离子放疗和质子束治疗)的疗效与安全性。汇总2年总生存率61.3%、无进展生存率37.9%、局部控制率82.2%,5年分别为41.3%、25.3%、61.5%;3/4级食管炎、皮炎、肺炎发生率分别为2.6%、2.6%、3.4%。

要点

  • 粒子治疗不可手术LA-NSCLC的2年OS 61.3%、PFS 37.9%、LC 82.2%。
  • 5年OS 41.3%、PFS 25.3%、LC 61.5%。
  • 同步放化疗(PBT联合同步化疗)组生存获益优于单纯PBT组和CIRT组。

核心结论

  • 粒子治疗在LA-NSCLC患者中显示出有前景的疗效和可接受的毒性。

研究设计与样本

  • 系统评价与Meta分析,检索PubMed、Web of Science、Embase和Cochrane Library截至2022年9月4日的文献。
  • 纳入19项符合条件的研究,总样本量为851例患者。
  • 主要终点为2年和5年局部控制率、总生存率和无进展生存率,次要终点为治疗相关毒性。
  • 采用STATA 15.1计算汇总临床结局及95%置信区间。

主要发现

  • 粒子治疗LA-NSCLC的2年OS为61.3%(95% CI=54.7-68.7%),2年PFS为37.9%(95% CI=33.8-42.6%),2年LC为82.2%(95% CI=78.7-85.9%)。
  • 5年OS为41.3%(95% CI=27.1-63.1%),5年PFS为25.3%(95% CI=16.3-39.4%),5年LC为61.5%(95% CI=50.7-74.6%)。
  • 按治疗类型分层亚组分析显示,同步放化疗(CCRT,PBT联合同步化疗)组生存获益优于PBT组和CIRT组。
  • 粒子治疗后LA-NSCLC患者3/4级食管炎发生率为2.6%(95% CI=0.4-6.0%),3/4级皮炎发生率为2.6%(95% CI=0.5-5.7%),3/4级肺炎发生率为3.4%(95% CI=1.4-6.0%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Particle therapy, mainly including carbon-ion radiotherapy (CIRT) and proton beam therapy (PBT), has dose distribution advantages compared to photon radiotherapy. It has been widely reported as a promising treatment method for early non-small cell lung cancer (NSCLC). However, its application in locally advanced non-small cell lung cancer (LA-NSCLC) is relatively rare, and its efficacy and safety are inconclusive. This study aimed to provide systematic evidence for evaluating the efficacy and safety of particle therapy for inoperable LA-NSCLC. METHODS: To retrieve published literature, a systematic search was conducted in PubMed, Web of Science, Embase, and Cochrane Library until September 4, 2022. The primary endpoints were local control (LC) rate, overall survival (OS) rate, and progression-free survival (PFS) rate at 2 and 5 years. The secondary endpoint was treatment-related toxicity. The pooled clinical outcomes and 95% confidence intervals (CIs) were calculated by using STATA 15.1. RESULTS: Nineteen eligible studies with a total sample size of 851 patients were included. The pooled data demonstrated that the OS, PFS, and LC rates at 2 years of LA-NSCLC treated by particle therapy were 61.3% (95% CI = 54.7-68.7%), 37.9% (95% CI = 33.8-42.6%) and 82.2% (95% CI = 78.7-85.9%), respectively. The pooled 5-year OS, PFS, and LC rates were 41.3% (95% CI = 27.1-63.1%), 25.3% (95% CI = 16.3-39.4%), and 61.5% (95% CI = 50.7-74.6%), respectively. Subgroup analysis stratified by treatment type showed that the concurrent chemoradiotherapy (CCRT, PBT combined with concurrent chemotherapy) group had better survival benefits than the PBT and CIRT groups. The incidence rates of grade 3/4 esophagitis, dermatitis, and pneumonia in LA-NSCLC patients after particle therapy were 2.6% (95% CI = 0.4-6.0%), 2.6% (95% CI = 0.5-5.7%) and 3.4% (95% CI = 1.4-6.0%), respectively. CONCLUSIONS: Particle therapy demonstrated promising efficacy and acceptable toxicity in LA-NSCLC patients.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Chen Y, Luo H, Liu R, et al. Efficacy and safety of particle therapy for inoperable stage II-III non-small cell lung cancer: a systematic review and meta-analysis. Radiat Oncol. 2023. PMID: 37217970. doi:10.1186/s13014-023-02264-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。